<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131177">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01978977</url>
  </required_header>
  <id_info>
    <org_study_id>CT/10.17</org_study_id>
    <nct_id>NCT01978977</nct_id>
  </id_info>
  <brief_title>Maintenance Bevacizumab or Observation After Taxane Based First Line Chemotherapy In Metastatic Breast Cancer</brief_title>
  <official_title>Maintenance Bevacizumab or Observation After Taxane Based First Line Chemotherapy Plus Bevacizumab in Women With HER2-Negative Metastatic Breast Cancer. An Observational Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hellenic Oncology Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hellenic Oncology Research Group</source>
  <oversight_info>
    <authority>Greece: National Organization of Medicines</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators propose to assess,the safety and tolerability profile (number of participants
      with adverse events)of bevacizumab (Avastin) when combined with standard chemotherapy as
      first line treatment of patients with metastatic Breast Cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nowadays in clinical practice patients with previously untreated metastatic breast cancer
      often receive taxane-based chemotherapy (paclitaxel or docetaxel) in combination with
      bevacizumab as it has been shown to increase progression-free survival. There is currently
      minimal information whether bevacizumab should be given as maintenance therapy after
      discontinuation of chemotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort</study_design>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>Every 2 or 3 weeks up to 12 or 18 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>In this observational study investigators are going to assess standard schedules  in which administration was every 2 or 3 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Response Rate</measure>
    <time_frame>Disease evaluation at Week 3 or at week 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>In this observational study investigators are going to assess standard schedules in which the disease evaluation was performed every 3 or 6 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients with Progression Free Survival</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients Overall Survival</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Avastin regimens</arm_group_label>
    <description>Patients who are going to receive chemotherapy plus Avastin (bevacizumab)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Clinics for cancer prevention
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Age ≥18 years

          -  Patients with histologically or cytologically confirmed, HER2-negative, metastatic
             Breast Cancer

          -  No prior first line treatment for metastatic Breast Cancer

          -  Previous hormonotherapy for metastatic Breast Cancer is allowed

          -  One or more measurable lesions (≥1cm in diameter with spiral CT scan or ≥2cm    with
             conventional techniques) according to RECIST criteria

          -  ECOG performance status ≤2

          -  Adequate haematological, renal and hepatic function

          -  Urine protein &lt;2+ (dipstick)

          -  Life expectancy of ≥12 weeks

        Exclusion Criteria:

          -  Previous first line treatment for metastatic colorectal cancer(progression &gt;12 months
             after the end of adjuvant treatment)

          -  Previous radiotherapy to target lesions

          -  Patients with brain metastases and/or cancerous meningitis

          -  Presence or history of other neoplasm except properly treated basal cell skin cancer
             or in situ cervical carcinoma

          -  Patients participating in interventional clinical trial
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vassilis Georgoulias, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hellenic Oncology Research Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vassilis Georgoulias, MD</last_name>
    <phone>+302810392750</phone>
    <email>georgulv@otenet.gr</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital of Crete, Dep of Medical Oncology</name>
      <address>
        <city>Heraklion</city>
        <state>Crete</state>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Maragkoudaki</last_name>
      <phone>+302810392570</phone>
      <email>evamaragoud@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dimitris Mavrudis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Alexandroupolis, Dept. of Medical Oncology</name>
      <address>
        <city>Alexandroupolis</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stylianos Kakolyris, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Nikolaos Xenidis, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Stelios Kakolyris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Air Forces Military Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikos Fytrakis</last_name>
      <phone>2107715690</phone>
      <email>nikos251@yahoo.gr</email>
    </contact>
    <investigator>
      <last_name>Nikos Kentepozidis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>&quot;IASO&quot; General Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stylianos Giassas, MD</last_name>
    </contact>
    <investigator>
      <last_name>Stylianos Giassas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>&quot;Metaxa's&quot; Anticancer Hospital of Piraeus, 1st Dep of Medical Oncology</name>
      <address>
        <city>Piraeus</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikolaos Ziras, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nikolaos Ziras, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>&quot;Theagenion&quot; Anticancer Hospital of Thessaloniki, 2nd Dep of Medical Oncology</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ioannis Mpoukovinas, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ioannis Mpoukovinas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 3, 2013</lastchanged_date>
  <firstreceived_date>November 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mBC</keyword>
  <keyword>HER2 negative</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Anti-angiogenic agent</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>1st Line</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
